Project Details
Description
A Phase 3b, Multicenter, Single-arm, Expanded Access Protocol of Tarlatamab (AMG 757) for the Treatment of Subjects with Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
| Status | Active |
|---|---|
| Effective start/end date | 3/29/24 → 3/31/34 |
Funding
- AMGEN INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.